PrimegeGene PharmaTech Co., Ltd. completed its listing on the New Third Board (stock code: 873969) on December 7, 2022, following the completion of its Series A+ round of financing of over RMB 100 million in the third quarter, further accelerating the company's capitalization process. The financing and listing will help the company further promote multiple R&D projects and clinical programs, and support the company to improve the construction of small molecule design platform, specialty multi-antibody macromolecule platform and formulation technology platform. This round of financing was led by K2 Venture Partners and followed by K2 Venture Partners, Sunland Fund and Tongxi management. StartPointAdvisors acted as the exclusive financial advisor in this transaction.

PrimegeGene was founded in 2016, with a senior management team consisting of entrepreneurs and scientists with deep industrial background. The Chairman, Mr. Li Yuliang, has more than 20 years of experience in industrial operation and management and investment, and is deeply involved in the pharmaceutical industry, while the CEO, Dr. Du Yunlong, has more than 20 years of working experience in famous multinational pharmaceutical companies, such as Pfizer and GSK, and has experience in the whole process of early development, phase 1-4 clinical trials, medical affairs, drug safety management, and NDA listing in the therapeutic areas of dermatology, metabolism, and neuroscience.

PrimegeGene has now formed a pharmaceutical company that specializes in topical drugs and has a multi-disciplinary layout in skin, ophthalmology, respiratory and other areas. The evaluation of the first PG-011 for the treatment of mild-to-moderate atopic dermatitis has completed a phase II clinical study, and the phase II clinical study for the treatment of mild-to-moderate nodular itchy rash is in the process of orderly advancement, and the product is undergoing phase II/III clinical expansion for several other indications.

Dr. Yunhai Wang, representative of the investors in this round, said, "The immune disease market is huge, and PrimegeGene's featured products in the fields of dermatology, ophthalmology, and respiratory are expected to address the unmet clinical needs in this field and provide better therapeutic drugs for related diseases. With its advanced level of technology development, excellent innovation capability and rich management experience, we are firmly optimistic about PrimegeGene's future development."

Mr. Li Yuliang, Chairman of PrimegeGene, said, "We are very grateful to K2 Venture Partners and other new and existing investors for their high recognition and trust in PrimegeGene. PrimegeGene has achieved significant milestones in the field of immune diseases, especially in the field of topical drugs, thanks to its unique product portfolio and technological advantages, as well as its well-established R&D and industrialization system. We will continue to innovate and develop PrimegeGene into a leading international pharmaceutical company in the field of topical drugs."

Dr. Du Yunlong, CEO of PrimegeGene, said, "On the basis of accelerating the R&D advancement of our existing products, we will continue to strengthen the layout of our product pipeline featuring topical medicines, closely focusing on immune disorders, in order to provide better medicines for patients."

Mr. Fu Jia, Managing Director of StartPointAdvisors, said, "PrimegeGene's products have hit the current practical clinical needs in Specialty areas such as dermatology, ophthalmology, and respiratory, with leading product progress, balanced pipeline configuration, and strong certainty of the company's development. We are very optimistic about the commercialization prospects of the company's products after they are launched in the market in the future."

Dr. Jiabao Wang, Senior Vice President of StartPointAdvisors, said, "PrimegeGene has both hard R&D strengths, and has also built a comprehensive system for the industrialization of innovative medicines, achieving effective management of the entire lifecycle from R&D, quality, to PV, and real-world data, and has excellent qualities in terms of corporate operations management and commercialization potential, and we look forward to more progress in the future for the company. "

About PrimegeGene

PrimegeGene focuses on the research, development and industrialization of innovative drugs with clinical advantages in the treatment of immune diseases with unmet clinical needs, including dermatological, ophthalmological, rhinological and other immune diseases, autoimmune diseases, inflammatory and rare diseases, etc.; the company's core product, PG-011, is a topical selective small-molecule inhibitor, and the first JAK multifunctional small-molecule compound to enter the clinic for the balance between inflammation and immunomodulation, as well as tissue repair; the company's founding team consists of entrepreneurs with mature pharmaceutical industry operation and management experience and industrial scientists with years of experience in multinational pharmaceutical companies. Our core product PG-011 is a topical selective small molecule inhibitor, which is the first JAK multifunctional small molecule compound that combines inflammation and immunomodulation with tissue repair. The company has established a platform for new drug design and discovery, biological evaluation of immunity and inflammation, clinical translational medicine for immunity and inflammation diseases, synthetic process R&D platform, quality management system and topical drug formulation R&D platform, and possesses a complete technical capability from R&D front-end to back-end clinical R&D; the company is a "specialized, fine, special, and new" small and medium-sized enterprise of Beijing, and a key enterprise of Beijing in the field of pharmaceutical and healthcare.

About K2 Venture Partners

K2 Venture Partners is an early-stage venture capital fund focused on the life sciences and healthcare sectors. K2 Venture Partners manages dual-currency funds in both RMB and USD, and has systematically laid out cutting-edge directions in gene therapy, gene editing, RNAi, mRNA, cyclic RNA, antibody-coupled drugs, bispecific antibodies, and surgical robots.

About lapamcapital

Lapamcapital is a leading professional investment organization in the biopharmaceutical field in China, with over 90% of its investment in the biopharmaceutical field. The number of NDAs (New Drug Applications) and new drug approvals in the portfolio accounts for a high proportion of NDAs and new drug approvals of domestic pharmaceutical companies in the same period.

About Sunland Fund

Sunland Fund is a specialized fund focusing on early-stage investments in the healthcare industry, focusing on innovative medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive surgical devices, and medical robots), innovative biopharmaceuticals, life science and technology, healthcare services, and other high-growth segments. We have invested in more than 50 medical and pharmaceutical star companies.

About Tongxi management

Tongxi management is comprised of experienced industrialists who are optimistic about the cross-cycle investment attributes of the pharmaceutical industry.

About StartPointAdvisors

StartPointAdvisors is a financial advisory firm specializing in the healthcare industry, with a team of experienced professionals from well-known institutions in the industry. StartPointAdvisors is headquartered in Beijing, with offices in Shanghai, Suzhou, Hangzhou and Guangzhou. Since its establishment, the firm has completed the full coverage of the healthcare track, has a good reputation and word of mouth in the industry, and is currently one of the most representative new investment banks in the domestic healthcare field.